(Q45168977)

10 December 2017

title

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene (English)

1 reference

10 December 2017

0 references

1 reference

2

1 reference

10 December 2017

Elizabeth Barrett-Connor

3

object named as

Elizabeth Barrett-Connor

1 reference

10 December 2017

8

Steven R Cummings

1 reference

10 December 2017

Silvana Martino

1

1 reference

10 December 2017

Trevor J Powles

4

1 reference

10 December 2017

John Mershon

5

1 reference

10 December 2017

Damon Disch

6

1 reference

10 December 2017

Roberta J Secrest

7

1 reference

10 December 2017

CORE Investigators

9

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Journal of the National Cancer Institute

10 December 2017

published in

1 reference

10 December 2017

volume

96

1 reference

10 December 2017

issue

23

1 reference

10 December 2017

page(s)

1751-1761

1 reference

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Molecular determinants of tissue selectivity in estrogen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Design and methods of the Raloxifene Use for The Heart (RUTH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH319

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJH319

1 reference

10 December 2017

1 reference